WallStSmart

Intelligent Bio Solutions Inc. (INBS)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1680528% more annual revenue ($65.77B vs $3.91M). MRK leads profitability with a 13.6% profit margin vs -296.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).

INBS

Hold

38

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 2/9Altman Z: -14.28

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INBSSignificantly Overvalued (-26.5%)

Margin of Safety

-26.5%

Fair Value

$4.15

Current Price

$1.97

$2.18 premium

UndervaluedFair: $4.15Overvalued
MRKSignificantly Overvalued (-52.4%)

Margin of Safety

-52.4%

Fair Value

$81.10

Current Price

$124.41

$43.31 premium

UndervaluedFair: $81.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INBS3 strengths · Avg: 9.7/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
45.5%10/10

Revenue surging 45.5% year-over-year

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$308.90B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.50M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-170.2%2/10

ROE of -170.2% — below average capital efficiency

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

INBS profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.17 — expect wider price swings.

INBS is growing revenue faster at 45.5% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a cutting-edge biotechnology company focused on pioneering advanced diagnostic solutions and biomarker-driven technologies specifically designed for drug abuse testing and monitoring. By leveraging innovative scientific methodologies, INBS provides rapid and precise testing options that facilitate timely clinical decision-making and enhance patient outcomes. As the healthcare landscape increasingly demands sophisticated diagnostic tools, INBS is well-positioned to spearhead advancements in healthcare diagnostics, reaffirming its dedication to elevating healthcare quality and operational efficiency.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?